Bupropion (Zyban) for Smoking Cessation: Evidence and Comparisons

Bupropion is the most commonly overlooked prescription quit method. A Cochrane review of 46 trials found that it roughly doubles six-month quit rates compared to placebo, with a relative risk of 1.64 [1]. In absolute terms, about 15-20% of bupropion users remain smoke-free at six months, compared to about 8-10% with placebo. That is comparable to single NRT and modestly below varenicline. Where bupropion has a specific advantage is for smokers with co-occurring depression or anxiety: it is licensed for both conditions and addresses both simultaneously.

How bupropion works for cessation

Bupropion is a norepinephrine and dopamine reuptake inhibitor. Its mechanism for smoking cessation is not fully understood, but it appears to work through two overlapping pathways. First, by increasing dopamine availability in the mesolimbic system, it partially substitutes for the dopamine release that nicotine provides, reducing the reward deficit that drives withdrawal-related cravings. Second, by increasing norepinephrine, it reduces the negative affect, the low mood, irritability and difficulty concentrating, that characterizes the first weeks without nicotine. Unlike NRT or varenicline, it does not act directly on nicotine receptors. This means it does not block or mimic the nicotine signal itself; it works downstream, on the neurochemical consequences of nicotine’s absence.

The standard cessation course starts one to two weeks before the quit date, at 150 mg once daily for three days, then 150 mg twice daily for 7 to 12 weeks. Starting before the quit date allows the drug to reach effective plasma levels before withdrawal begins, which is important because bupropion’s effects on mood and craving take several days to develop. Most prescribers recommend setting the quit date for the second week of treatment. Some patients continue beyond 12 weeks if relapse risk is high, though the evidence for extended use is limited.

The drug comes in a sustained-release formulation for cessation use. The immediate-release form, used in some depression contexts, has a higher peak concentration and a greater seizure risk, which is why the cessation formulation specifically uses the sustained-release version.

The seizure question, in context

Bupropion carries a real but rare seizure risk. At the standard cessation dose of 300 mg per day, the incidence is approximately 1 in 1,000 (0.1%), based on surveillance data from over 3,100 patients [4]. That rate is comparable to other antidepressants at their standard doses. The risk is dose-dependent: it increases substantially at doses above 450 mg per day, which is above the standard cessation dose and above the recommended maximum for any indication.

Bupropion is contraindicated in people with a history of seizures, eating disorders (bulimia and anorexia nervosa increase seizure risk through electrolyte disturbances and altered seizure thresholds), or who are currently withdrawing from alcohol or benzodiazepines. It should also be used with caution in patients on other medications that lower the seizure threshold.

This risk should be understood in proportion. The 0.1% seizure rate at standard doses is low enough that bupropion is one of the most widely prescribed antidepressants in the US, with millions of prescriptions annually. The concern is real; the incidence does not justify avoiding the drug for most people. The prescriber conversation should cover seizure history and contraindications, and then the risk can be weighed against the substantial benefit of doubling quit rates.

How bupropion compares to other methods

Method	Six-month quit rate vs. placebo	Mechanism	Main side effects	Prescription required	Notes
Bupropion	~1.5-2x placebo (~15-20%)	NE/DA reuptake inhibitor	Insomnia, dry mouth, seizure (rare)	Yes	Also treats depression
Varenicline	~3x placebo (~25-30%)	Partial nicotine receptor agonist	Nausea, insomnia	Yes	Strongest single method
Nicotine patch (single)	~2x placebo (~15-20%)	Steady-state transdermal nicotine	Skin irritation, dreams	No	Available OTC
Combination NRT	~15-25% higher than patch alone	Baseline + on-demand nicotine	Combined NRT side effects	No	Underused

In head-to-head trials, varenicline outperforms bupropion [2] [3]. The EAGLES trial, a multinational randomized trial of 8,144 participants, confirmed this directly: varenicline produced higher quit rates than bupropion, which in turn outperformed placebo. Both drugs had similar psychiatric safety profiles across the full sample, including participants with a history of psychiatric disorders [2]. The Jorenby trial, a three-arm comparison of 1,025 participants, reached the same conclusion: varenicline was superior to bupropion, and bupropion was superior to placebo [3].

For the smoker choosing between bupropion and varenicline purely on cessation efficacy, varenicline is the higher-yield option. Bupropion’s value lies in specific situations: co-occurring depression, intolerance to varenicline (nausea is the most common reason people stop varenicline), or a preference for a non-nicotine medication approach.

Compared to single NRT, bupropion performs similarly. The Cochrane relative risk for NRT is approximately 1.55; for bupropion it is 1.64 [1]. The confidence intervals overlap. In practice, the choice between bupropion and a nicotine patch often comes down to whether the smoker prefers a prescription medication or an over-the-counter product, and whether co-occurring depression shifts the calculation.

The depression connection

About 40-50% of cigarettes in the US are smoked by people with mental health conditions. Depression and smoking are strongly associated: smoking rates in people with major depressive disorder are roughly twice those in the general population. Quitting can temporarily worsen depressive symptoms during the withdrawal period, because nicotine provides a short-term mood lift that masks underlying mood instability. This creates a practical problem: the quit attempt triggers a mood dip, the mood dip triggers a relapse, and the cycle repeats.

Bupropion is the only cessation medication that is also an antidepressant, which makes it a practical choice for smokers with active depression or a history of depression. By maintaining mood during the withdrawal period, it can reduce the risk of relapse triggered by negative affect.

The evidence does not show that bupropion is dramatically more effective for smoking cessation in depressed smokers specifically than in the general smoking population [1]. The Cochrane data suggests similar relative effectiveness across populations. What bupropion does offer is a single medication that addresses both the cessation goal and the mood management, which simplifies the treatment plan and avoids the need for a separate antidepressant during the quit attempt. For clinicians managing patients with both conditions, this is a meaningful advantage in treatment simplicity and adherence.

Side effects beyond seizure risk

The most common side effects are insomnia and dry mouth. Insomnia is often managed by taking the second dose earlier in the day, no later than mid-afternoon, rather than in the evening. Dry mouth is usually mild and does not require intervention. Headache occurs in some patients but is typically transient.

Weight gain is less of an issue with bupropion than with other cessation approaches. Quitting smoking typically leads to weight gain of 4-5 kg in the first year, driven by both metabolic changes and increased appetite. Bupropion may actually attenuate this weight gain, which is a practical consideration for smokers who cite weight concerns as a reason not to quit. The effect is modest, not a weight-loss drug by any measure, but it contrasts with the tendency for other cessation methods to have no effect on post-cessation weight gain or, in the case of NRT, only a slight delay.

What this means if you’re deciding

If you have co-occurring depression and smoke, bupropion is worth discussing with your prescriber before other cessation medications. It addresses both conditions with a single medication, avoids the weight gain concern, and has a well-established safety profile at standard doses. The quit rate is lower than varenicline, but for a smoker whose previous quit attempts failed partly because of mood destabilization, the mood support may be more important than the raw efficacy difference.

If you do not have co-occurring depression and want the highest-efficacy single method, varenicline is the stronger option. If you want to avoid prescription medication entirely, combination NRT (patch plus gum or lozenge) performs at least as well as bupropion and is available over the counter.

For smokers with COPD, bupropion has been studied with modest results in COPD-specific trials [5]. Quitting is the single most effective intervention for slowing COPD progression, and the choice of cessation method matters because of the high stakes. Varenicline and combination NRT have stronger evidence in this population, but bupropion remains an option when other methods are not tolerated or when co-occurring depression complicates the picture.

Open questions

Whether combining bupropion with NRT produces better outcomes than either alone is supported by some evidence but not settled. A few trials have found modestly higher quit rates with the combination, but the effect is not consistent across studies, and the additional side effect burden (insomnia from bupropion plus skin irritation from the patch, for example) reduces adherence in some patients.

Combining bupropion with varenicline has been explored in small studies with mixed results. The theoretical rationale, combining two different mechanisms, is sound, but the clinical evidence does not yet clearly show that the combination outperforms varenicline alone. The additional cost and side effect burden of a second prescription medication may not be justified until larger trials produce clearer results. The evidence does not yet support triple therapy (bupropion plus combination NRT) over the best two-method combinations.

A doctor or pharmacist can help choose the right approach for your health history. The Quitline (1-800-QUIT-NOW) provides free coaching and can sometimes supply NRT.